Based on the same decision tree algorithm that we used in cohort B (Figure 1B), 32 tumours were classified in the HER2-positive group, 111 in group 1 (HER2-negative, ER-positive tumours with intermediate ALCAM and low OPN), 17 in group 2 (HER2/ER-negative tumours with high OPN and low ALCAM expression) and 21 in group 3 (HER2/ER-negative tumours with predominantly higher OPN and ALCAM expression). The gene discussed is ALCAM; the disease is neoplasm.